The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

by Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu de Sousa, Deolinda Sousa Pereira, Marina Borges
Published 2021-09-01